Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Jumped Today

By Joe Tenebruso – Aug 21, 2020 at 3:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A regulatory review of the biotech's experimental coronavirus vaccine could come as early as October.

What happened

Shares of BioNTech (BNTX -0.14%) climbed on Friday after the biotechnology company and its pharmaceutical partner Pfizer (PFE -0.61%) released positive data related to their COVID-19 vaccine candidate. As of 3:40 p.m. EDT, BioNTech's stock was up 10% after rising as much as 15% earlier in the day. 

So what 

BioNTech and Pfizer's coronavirus vaccine candidate, BNT162b2, showed a strong ability to provoke an immune response in both young and older adults. It was also generally well tolerated; fewer than 20% of the study's participants experienced mild to moderate fever, and only a small number suffered more severe events, such as muscle and joint pain, which were temporary and manageable. 

A person is pointing to an upwardly sloping line.

BioNTech's stock rose sharply on Friday. Image source: Getty Images.

The promising results from their phase 1 study prompted BioNTech and Pfizer to advance BNT162b2 into a phase 2/3 trial. The companies intend to enroll as many as 30,000 participants in the study, of which 11,000 have already been dosed.

Now what

Should their vaccine candidate continue to demonstrate positive results, Pfizer and BioNTech hope to obtain a regulatory review for BNT162b2 as early as October. And if regulators approve the vaccine, the companies say they could supply up to 100 million doses by the end of this year and as many as 1.3 billion doses by the end of 2021.

Pfizer and BioNTech reached an agreement with the U.S. government in July, under which they'll be paid $1.95 billion in exchange for 100 million doses of the vaccine, should it prove both safe and effective. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$133.60 (-0.14%) $0.19
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.16 (-0.61%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.